For Institutions
About
Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026
Wave Life Sciences surged 147% due to robust preliminary clinical data for its RNA-targeted obesity treatment, WVE-007. The data showed significant fat reduction and increased lean muscle mass, prompting a re-rating of the stock. This surge reflects the potential of Wave's RNA platform and its broader pipeline, despite the early-stage nature of the trial. Investors are now focusing on the company's potential in next-generation metabolic therapies.
Eli Lilly shares have climbed in the double digits this year.
Johnson & Johnson announced FDA approval for its prostate cancer therapy, Akeega plus prednisone, targeting metastatic castration-sensitive prostate cancer with BRCA mutation. The approval follows a phase 3 study showing a 54% reduction in radiographic progression or death risk and a 59% delay in symptomatic progression. The safety profile aligns with other FDA-approved therapies.
Johnson & Johnson was hit with a $40 million verdict by the Los Angeles Superior Court over talc-based baby powder allegedly causing ovarian cancer. The award covers compensatory damages for plaintiffs Monica Kent and Deborah Schultz and Schultz's husband. The verdict followed a four-week trial with testimony from former FDA commissioner David Kessler. More trials are expected through H1 2026. Johnson & Johnson did not immediately respond to requests for comment.
